Index of /Coronavirus_(Wuhan_2019-nCov)/Covid-19_Vaccines/Pfizer_document_releases/March_2022

[ICO]NameLast modifiedSizeDescription
[PARENTDIR]Parent Directory  -  
[ ]125742_S1_M1_356h.pdf2022-04-05 14:41 714K 
[ ]125742_S1_M1_3674.pdf2022-04-05 14:41 5.1M 
[ ]125742_S1_M1_cover.pdf2022-04-05 14:42 1.3M 
[ ]125742_S1_M1_debarment.pdf2022-04-05 14:42 656K 
[ ]125742_S1_M1_exclusivity-claim.pdf2022-04-05 14:43 616K 
[ ]125742_S1_M1_fast-track-designation.pdf2022-04-05 14:43 649K 
[ ]125742_S1_M1_financial-cert-3454.pdf2022-04-05 14:43 3.4M 
[ ]125742_S1_M1_financial-cert-bias.pdf2022-04-05 14:44 696K 
[ ]125742_S1_M1_ipsp-agreed-letter.pdf2022-04-05 14:44 658K 
[ ]125742_S1_M1_priority-review-request-1.pdf2022-04-06 16:14 2.4M 
[ ]125742_S1_M1_priority-review-request.pdf2022-04-05 14:41 1.6M 
[ ]125742_S1_M1_trans-of-oblig.pdf2022-04-05 14:46 717K 
[ ]125742_S1_M1_us-agent-authorization.pdf2022-04-05 14:46 1.0M 
[ ]125742_S1_M1_userfee.pdf2022-04-05 14:47 628K 
[ ]125742_S1_M1_waiver-req-designated-suffix.pdf2022-04-05 14:48 2.7M 
[ ]125742_S1_M2_22_introduction.pdf2022-04-05 14:48 670K 
[ ]125742_S1_M2_24_nonclinical-overview.pdf2022-04-05 14:50 1.6M 
[ ]125742_S1_M2_26_pharmkin-tabulated-summary.pdf2022-04-05 14:51 1.3M 
[ ]125742_S1_M2_26_pharmkin-written-summary.pdf2022-04-05 14:51 1.4M 
[ ]125742_S1_M2_27_literature-references.pdf2022-04-05 14:45 1.7M 
[ ]125742_S1_M2_27_synopses-indiv-studies.pdf2022-04-05 14:45 1.7M 
[ ]125742_S1_M4_4223_185350.pdf2022-04-05 14:56 1.4M 
[ ]125742_S1_M4_4223_R-20-0072.pdf2022-04-05 14:56 5.2M 
[ ]125742_S1_M5_5351_c4591001-ad-hoc-label-tables.pdf2022-04-05 14:57 889K 
[ ]125742_S1_M5_5351_c4591001-fa-interim-compliance-sensitive.pdf2022-04-05 15:03 1.3M 
[ ]125742_S1_M5_5351_c4591001-fa-interim-compliance.pdf2022-04-05 15:03 2.0M 
[ ]125742_S1_M5_5351_c4591001-fa-interim-efficacy-response.pdf2022-04-05 15:04 2.4M 
[ ]125742_S1_M5_5351_c4591001-fa-interim-errata.pdf2022-04-05 15:04 2.3M 
[ ]125742_S1_M5_5351_c4591001-fa-interim-excluded-patients-sensitive.pdf2022-04-05 14:53 16M 
[ ]125742_S1_M5_5351_c4591001-fa-interim-excluded-patients.pdf2022-04-05 15:05 1.8M 
[ ]125742_S1_M5_5351_c4591001-fa-interim-lab-measurements-sensitive.pdf2022-04-05 15:23 4.8M 
[ ]125742_S1_M5_5351_c4591001-fa-interim-lab-measurements.pdf2022-04-05 14:55 12M 
[ ]125742_S1_M5_5351_c4591001-fa-interim-oversight-committees.pdf2022-04-05 15:25 2.3M 
[ ]125742_S1_M5_5351_c4591001-fa-interim-protocol.pdf2022-04-05 15:07 31M 
[ ]125742_S1_M5_5351_c4591001-interim-mth6-oversight-committees.pdf2022-04-05 15:11 13M 
[ ]125742_S1_M5_5351_c4591001-interim-mth6-protocol.pdf2022-04-05 15:18 37M 
[ ]125742_S1_M5_CRF_c4591001-1085-10851018.pdf2022-04-05 15:39 2.3M 
[ ]125742_S1_M5_CRF_c4591001-1085-10851116.pdf2022-04-05 15:40 1.2M 
[ ]125742_S1_M5_CRF_c4591001-1085-10851129.pdf2022-04-05 15:40 1.9M 
[ ]125742_S1_M5_CRF_c4591001-1085-10851216.pdf2022-04-05 15:44 1.2M 
[ ]125742_S1_M5_CRF_c4591001-1085-10851246.pdf2022-04-05 15:43 1.1M 
[ ]125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.pdf2022-04-05 15:20 602K 
[ ]125742_S1_M5_c4591001-A-adrg.pdf2022-04-05 15:21 1.5M 
[ ]125742_S1_M5_c4591001-A-bmi-12-15-scale.pdf2022-04-05 15:21 627K 
[ ]125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.pdf2022-04-05 15:22 634K 
[ ]125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.pdf2022-04-05 15:22 620K 
[ ]125742_S1_M5_c4591001-A-comorbidity-categories.pdf2022-04-05 15:28 637K 
[ ]125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.pdf2022-04-05 15:29 607K 
[ ]125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.pdf2022-04-05 15:29 846K 
[ ]125742_S1_M5_c4591001-A-report-cci-aids-hiv.pdf2022-04-05 15:29 629K 
[ ]125742_S1_M5_c4591001-A-report-cci-any-malignancy.pdf2022-04-05 15:30 670K 
[ ]125742_S1_M5_c4591001-A-report-cci-cerebrovascular.pdf2022-04-05 15:25 632K 
[ ]125742_S1_M5_c4591001-A-report-cci-chf.pdf2022-04-05 15:26 628K 
[ ]125742_S1_M5_c4591001-A-report-cci-dementia.pdf2022-04-05 15:27 626K 
[ ]125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.pdf2022-04-05 15:27 626K 
[ ]125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.pdf2022-04-05 15:28 627K 
[ ]125742_S1_M5_c4591001-A-report-cci-hemiplegia.pdf2022-04-05 15:36 626K 
[ ]125742_S1_M5_c4591001-A-report-cci-leukemia.pdf2022-04-05 15:36 631K 
[ ]125742_S1_M5_c4591001-A-report-cci-lymphoma.pdf2022-04-05 15:36 640K 
[ ]125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.pdf2022-04-05 15:33 636K 
[ ]125742_S1_M5_c4591001-A-report-cci-mi.pdf2022-04-05 15:33 624K 
[ ]125742_S1_M5_c4591001-A-report-cci-mild-liver.pdf2022-04-05 15:33 628K 
[ ]125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.pdf2022-04-05 15:34 626K 
[ ]125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.pdf2022-04-05 15:34 625K 
[ ]125742_S1_M5_c4591001-A-report-cci-periph-vasc.pdf2022-04-05 15:34 632K 
[ ]125742_S1_M5_c4591001-A-report-cci-pulmonary.pdf2022-04-05 15:35 630K 
[ ]125742_S1_M5_c4591001-A-report-cci-renal.pdf2022-04-05 15:41 629K 
[ ]125742_S1_M5_c4591001-A-report-cci-rheumatic.pdf2022-04-05 15:41 629K 
[ ]125742_S1_M5_c4591001-T-S-final-reacto-tables-track.pdf2022-04-05 15:42 2.2M 
[ ]125742_S1_M5_c4591001-T-S-roadmap.pdf2022-04-05 15:42 703K 
[ ]125742_S1_M5_c4591001-T-S-summary-differences-csr-vs-update.pdf2022-04-05 15:37 667K 
[ ]125742_S1_M5_c4591001-T-S-suppl-arg.pdf2022-04-05 15:37 738K 
[ ]125742_S1_M5_c4591001-T-S-updated-reacto-tlf.pdf2022-04-05 15:39 17M 
[TXT]FDA-CBER-2021-5683-0021888-to-0021901_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf1-sas.txt2022-04-05 15:43 14K 
[TXT]FDA-CBER-2021-5683-0021902-to-0021915_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf2-sas.txt2022-04-05 15:43 15K 
[TXT]FDA-CBER-2021-5683-0021916-to-0021929_125742_S1_M5_c4591001-A-P-adae-s092-all-unb-p3-saf-sas.txt2022-04-05 15:43 15K 
[TXT]FDA-CBER-2021-5683-0021930-to-0021943_125742_S1_M5_c4591001-A-P-adae-s092-cr-cut-p3x-saf-sas.txt2022-04-05 15:43 15K 
[TXT]FDA-CBER-2021-5683-0021944-to-0021963_125742_S1_M5_c4591001-A-P-adae-sas.txt2022-04-05 15:44 35K 
[TXT]FDA-CBER-2021-5683-0021964-to-0021980_125742_S1_M5_c4591001-A-P-adae-vax-tier2-p3-saf-sas.txt2022-04-05 15:44 18K 
[TXT]FDA-CBER-2021-5683-0021981-to-0022027_125742_S1_M5_c4591001-A-P-adc19ef-sas.txt2022-04-05 15:44 81K 
[TXT]FDA-CBER-2021-5683-0022028-to-0022040_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-sg-eval-sas.txt2022-04-05 15:44 20K 
[TXT]FDA-CBER-2021-5683-0022041-to-0022053_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-wo-sg-eval-sas.txt2022-04-05 15:46 19K 
[TXT]FDA-CBER-2021-5683-0022054-to-0022062_125742_S1_M5_c4591001-A-P-adc19ef-ve-sev-cov-pd1-aai-sas.txt2022-04-05 15:46 12K 
[TXT]FDA-CBER-2021-5683-0022063-to-0022135_125742_S1_M5_c4591001-A-P-adce-s010-lr-p3-saf-sas.txt2022-04-05 15:46 72K 
[TXT]FDA-CBER-2021-5683-0022136-to-0022325_125742_S1_M5_c4591001-A-P-adce-s020-se-p3-saf-sas.txt2022-04-05 15:46 193K 
[TXT]FDA-CBER-2021-5683-0022326-to-0022345_125742_S1_M5_c4591001-A-P-adcevd-sas.txt2022-04-05 15:47 27K 
[TXT]FDA-CBER-2021-5683-0022346-to-0022364_125742_S1_M5_c4591001-A-P-adcm-sas.txt2022-04-05 15:46 32K 
[TXT]FDA-CBER-2021-5683-0022365-to-0022560_125742_S1_M5_c4591001-A-P-adds-s002-all-p3-rand-sas.txt2022-04-05 15:46 156K 
[TXT]FDA-CBER-2021-5683-0022561-to-0022567_125742_S1_M5_c4591001-A-P-adds-sas.txt2022-04-05 15:46 11K 
[TXT]FDA-CBER-2021-5683-0022568-to-0022600_125742_S1_M5_c4591001-A-P-adfacevd-sas.txt2022-04-05 15:46 49K 
[TXT]FDA-CBER-2021-5683-0022601-to-0022617_125742_S1_M5_c4591001-A-P-admh-sas.txt2022-04-05 15:46 24K 
[TXT]FDA-CBER-2021-5683-0022618-to-0022691_125742_S1_M5_c4591001-A-P-adsl-demo-7d-eval-eff-sas.txt2022-04-05 15:48 75K 
[TXT]FDA-CBER-2021-5683-0022692-to-0022765_125742_S1_M5_c4591001-A-P-adsl-demo-7d-wwo-eval-eff-sas.txt2022-04-05 15:47 75K 
[TXT]FDA-CBER-2021-5683-0022766-to-0022792_125742_S1_M5_c4591001-A-P-adsl-fu-d2-p3-saf-sas.txt2022-04-05 15:47 29K 
[TXT]FDA-CBER-2021-5683-0022793-to-0022866_125742_S1_M5_c4591001-A-P-adsl-s005-demo-all-p3-saf-sas.txt2022-04-05 15:47 75K 
[TXT]FDA-CBER-2021-5683-0022867-to-0023006_125742_S1_M5_c4591001-A-P-adsl-sas.txt2022-04-05 15:47 197K 
[TXT]FDA-CBER-2021-5683-0023007-to-0023031_125742_S1_M5_c4591001-A-P-adsympt-sas.txt2022-04-05 15:47 43K 
[TXT]FDA-CBER-2021-5683-0023032-to-0023065_125742_S1_M5_c4591001-A-P-adva-sas.txt2022-04-05 15:47 45K 
[ ]FDA-CBER-2021-5683-0023490-to-0023491_125742_S1_M5_c4591001-A-bmi-12-15-scale-1.xlsx2022-04-05 15:48 13K 
[ ]FDA-CBER-2021-5683-0023490-to-0023491_125742_S1_M5_c4591001-A-bmi-12-15-scale.xlsx2022-04-05 15:47 13K 
[ ]FDA-CBER-2021-5683-0023500-to-0023507_125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.xlsx2022-04-05 15:51 29K 
[ ]FDA-CBER-2021-5683-0023523-to-0023538_125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.xlsx2022-04-05 15:51 18K 
[ ]FDA-CBER-2021-5683-0023540_125742_S1_M5_c4591001-A-comorbidity-categories.xlsx2022-04-05 15:51 19K 
[ ]FDA-CBER-2021-5683-0023550-to-0023569_125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.xlsx2022-04-05 15:51 22K 
[ ]FDA-CBER-2021-5683-0023711-to-0023875_125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.xlsx2022-04-05 15:52 84K 
[ ]FDA-CBER-2021-5683-0023878_125742_S1_M5_c4591001-A-report-cci-aids-hiv.xlsx2022-04-05 15:52 23K 
[ ]FDA-CBER-2021-5683-0023895-to-0023915_125742_S1_M5_c4591001-A-report-cci-any-malignancy.xlsx2022-04-05 15:52 35K 
[ ]FDA-CBER-2021-5683-0023919-to-0023921_125742_S1_M5_c4591001-A-report-cci-cerebrovascular.xlsx2022-04-05 15:52 12K 
[ ]FDA-CBER-2021-5683-0023924_125742_S1_M5_c4591001-A-report-cci-chf.xlsx2022-04-05 15:52 10K 
[ ]FDA-CBER-2021-5683-0023926_125742_S1_M5_c4591001-A-report-cci-dementia.xlsx2022-04-05 15:52 9.4K 
[ ]FDA-CBER-2021-5683-0023928_125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.xlsx2022-04-05 15:50 9.2K 
[ ]FDA-CBER-2021-5683-0023930_125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.xlsx2022-04-05 15:50 9.8K 
[ ]FDA-CBER-2021-5683-0023932_125742_S1_M5_c4591001-A-report-cci-hemiplegia.xlsx2022-04-05 15:50 9.6K 
[ ]FDA-CBER-2021-5683-0023936-to-0023937_125742_S1_M5_c4591001-A-report-cci-leukemia.xlsx2022-04-05 15:50 12K 
[ ]FDA-CBER-2021-5683-0023944-to-0023950_125742_S1_M5_c4591001-A-report-cci-lymphoma.xlsx2022-04-05 15:50 17K 
[ ]FDA-CBER-2021-5683-0023955-to-0023958_125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.xlsx2022-04-05 15:50 14K 
[ ]FDA-CBER-2021-5683-0023960_125742_S1_M5_c4591001-A-report-cci-mi.xlsx2022-04-05 15:50 8.9K 
[ ]FDA-CBER-2021-5683-0023963_125742_S1_M5_c4591001-A-report-cci-mild-liver.xlsx2022-04-05 15:50 10K 
[ ]FDA-CBER-2021-5683-0023965_125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.xlsx2022-04-05 15:50 9.2K 
[ ]FDA-CBER-2021-5683-0023967_125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.xlsx2022-04-05 15:50 9.2K 
[ ]FDA-CBER-2021-5683-0023971-to-0023972_125742_S1_M5_c4591001-A-report-cci-periph-vasc.xlsx2022-04-05 15:51 12K 
[ ]FDA-CBER-2021-5683-0023975-to-0023976_125742_S1_M5_c4591001-A-report-cci-pulmonary.xlsx2022-04-05 15:51 12K 
[ ]FDA-CBER-2021-5683-0023979-to-0023980_125742_S1_M5_c4591001-A-report-cci-renal.xlsx2022-04-05 15:51 11K 
[ ]FDA-CBER-2021-5683-0023983-to-0023984_125742_S1_M5_c4591001-A-report-cci-rheumatic.xlsx2022-04-05 15:51 24K 
[ ]FDA-CBER-2021-5683-0023987_125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.xlsx2022-04-05 15:51 21K 
Apache/2.4.29 (Ubuntu) Server at avalonlibrary.net Port 443